Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tvardi Therapeutics Inc (TVRD)

Tvardi Therapeutics Inc (TVRD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,371
  • Shares Outstanding, K 9,381
  • Annual Sales, $ 7,140 K
  • Annual Income, $ -70,870 K
  • EBIT $ -23 M
  • EBITDA $ -22 M
  • 60-Month Beta 0.11
  • Price/Sales 5.90
  • Price/Cash Flow N/A
  • Price/Book 1.51

Options Overview Details

View History
  • Implied Volatility 227.11% (+65.27%)
  • Historical Volatility 54.37%
  • IV Percentile 64%
  • IV Rank 36.11%
  • IV High 449.63% on 10/21/25
  • IV Low 101.35% on 11/21/25
  • Expected Move (DTE 6) 1.46 (33.15%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 20
  • Volume Avg (30-Day) 28
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 1,436
  • Open Int (30-Day) 1,553
  • Expected Range 2.95 to 5.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.55
  • Number of Estimates 3
  • High Estimate -0.49
  • Low Estimate -0.58
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.74 +17.91%
on 12/02/25
4.71 -6.37%
on 12/11/25
+0.17 (+4.01%)
since 11/12/25
3-Month
3.74 +17.91%
on 12/02/25
43.65 -89.90%
on 10/10/25
-29.47 (-86.98%)
since 09/12/25
52-Week
3.74 +17.91%
on 12/02/25
43.65 -89.90%
on 10/10/25
-5.01 (-53.17%)
since 12/12/24

Most Recent Stories

More News
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 4.41 (-1.78%)
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 4.41 (-1.78%)
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 4.41 (-1.78%)
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven...

TVRD : 4.41 (-1.78%)
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 4.41 (-1.78%)
Investors in Tvardi Therapeutics, Inc. (TVRD) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - November 13, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Tvardi Therapeutics, Inc. ("Tvardi Therapeutics, Inc.") (NASDAQ:...

TVRD : 4.41 (-1.78%)
Tvardi: Q3 Earnings Snapshot

Tvardi: Q3 Earnings Snapshot

TVRD : 4.41 (-1.78%)
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

On track for topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H1 2026 Results from healthy volunteer study of its next-generation STAT3...

TVRD : 4.41 (-1.78%)
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tvardi To Contact Him Directly To Discuss Their Options...

TVRD : 4.41 (-1.78%)
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven...

TVRD : 4.41 (-1.78%)

Business Summary

Tvardi Therapeutics Inc. is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Tvardi Therapeutics Inc., formerly known as Cara Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 4.72
2nd Resistance Point 4.64
1st Resistance Point 4.53
Last Price 4.41
1st Support Level 4.34
2nd Support Level 4.26
3rd Support Level 4.15

See More

52-Week High 43.65
Fibonacci 61.8% 28.40
Fibonacci 50% 23.70
Fibonacci 38.2% 18.99
Last Price 4.41
52-Week Low 3.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar